Rigvir Group made a strategic decision temporarily suspend the distribution of Rigvir in Latvia

Biotechnology company The Rigvir Group made a strategic decision on its own initiative, temporarily suspend the distribution of Rigvir medicines in Latvia, while maintaining the existing registration. Such decision is a logical and economically viable step that allows investment and administrative resources to be focused on the implementation of a coordinated research plan for the centralized registration in EU.

Contacts for Media Inquiries

Rigvir Group
Address: Atlasa street 7C, Riga, Latvia, LV-1026
Phone: +371 67 716 132
E-mail: pr@rigvir.com